Arkolith/Insider Trading/NKTR/Form 4

Zalevsky Jonathan

Chief R&D OfficerNEKTAR THERAPEUTICS (NKTR) · full profile →Form 4 · filed May 21, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$13K
Net Open-Market Flow
-$13K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 19, 2026Sell(S)199$65.51$13K21K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-235030) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML